Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy

Hiroki Ide, Jun Nakashima, Hidaka Kono, Eiji Kikuchi, Hirohiko Nagata, Akira Miyajima, Ken Nakagawa, Mototsugu Oya

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade ≥4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT ≥6), high-risk group (Gleason grade ≥4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate-and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level ≥2 at the initiation of HT. Primary Gleason grade ≥4 and PSA-DT <6 months are independent predictors. Patients in the intermediate-and high-risk groups may benefit from early HT for PSAR after surgery.

Original languageEnglish
Article numberhyp133
Pages (from-to)177-180
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume40
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
Disease-Free Survival
Therapeutics
Secondary Prevention
Multivariate Analysis
Survival Rate

Keywords

  • Gleason grade
  • Hormonal therapy
  • Prostate cancer
  • PSA doubling time
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. / Ide, Hiroki; Nakashima, Jun; Kono, Hidaka; Kikuchi, Eiji; Nagata, Hirohiko; Miyajima, Akira; Nakagawa, Ken; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. 2, hyp133, 02.2010, p. 177-180.

Research output: Contribution to journalArticle

Ide, Hiroki ; Nakashima, Jun ; Kono, Hidaka ; Kikuchi, Eiji ; Nagata, Hirohiko ; Miyajima, Akira ; Nakagawa, Ken ; Oya, Mototsugu. / Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. 2. pp. 177-180.
@article{6a476194f6884c269cbbfb031fc0a550,
title = "Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy",
abstract = "The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade ≥4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT ≥6), high-risk group (Gleason grade ≥4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate-and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level ≥2 at the initiation of HT. Primary Gleason grade ≥4 and PSA-DT <6 months are independent predictors. Patients in the intermediate-and high-risk groups may benefit from early HT for PSAR after surgery.",
keywords = "Gleason grade, Hormonal therapy, Prostate cancer, PSA doubling time, Radical prostatectomy",
author = "Hiroki Ide and Jun Nakashima and Hidaka Kono and Eiji Kikuchi and Hirohiko Nagata and Akira Miyajima and Ken Nakagawa and Mototsugu Oya",
year = "2010",
month = "2",
doi = "10.1093/jjco/hyp133",
language = "English",
volume = "40",
pages = "177--180",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy

AU - Ide, Hiroki

AU - Nakashima, Jun

AU - Kono, Hidaka

AU - Kikuchi, Eiji

AU - Nagata, Hirohiko

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Oya, Mototsugu

PY - 2010/2

Y1 - 2010/2

N2 - The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade ≥4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT ≥6), high-risk group (Gleason grade ≥4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate-and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level ≥2 at the initiation of HT. Primary Gleason grade ≥4 and PSA-DT <6 months are independent predictors. Patients in the intermediate-and high-risk groups may benefit from early HT for PSAR after surgery.

AB - The present study was undertaken to investigate the predictors in patients who received hormonal therapy (HT) for prostate-specific antigen recurrence (PSAR) after surgery. Predictors for the progression-free survival were assessed in 55 patients who received HT for PSAR after surgery. In multivariate analysis, primary Gleason grade ≥4 and PSA doubling time (PSA-DT) <6 months were independent predictors. The patients were stratified into low-risk group (Gleason grade <4 and PSA-DT ≥6), high-risk group (Gleason grade ≥4 and PSA-DT <6) and intermediate-risk group (all others). In the intermediate-and high-risk groups, progression-free survival rate was significantly higher in patients with PSA level <2 than in those with PSA level ≥2 at the initiation of HT. Primary Gleason grade ≥4 and PSA-DT <6 months are independent predictors. Patients in the intermediate-and high-risk groups may benefit from early HT for PSAR after surgery.

KW - Gleason grade

KW - Hormonal therapy

KW - Prostate cancer

KW - PSA doubling time

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=77449145412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449145412&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyp133

DO - 10.1093/jjco/hyp133

M3 - Article

C2 - 19837688

AN - SCOPUS:77449145412

VL - 40

SP - 177

EP - 180

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

M1 - hyp133

ER -